https://doi.org/10.4081/hmr.v2i5.743

Pha-739358: a pan-aurora kinase inhibitor

Vol. 2 No. 5: New Drugs in Hematology, Bologna, Italy 5-7 October 2008
Published: June 23, 2009
Abstract Views: 225
Untitled (): 0
PDF: 424
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

R Paquette
support@pagepress.org
N Shah
C Sawyers
G Martinelli
J Nicoll
M Chalukya
PHA-739358 is a small molecule 3-aminopyrazole derivative with low nanomolar activity against all aurora kinases (AKs). It also inhibits other cancer relevant tyrosine kinases such as wild type and mutated ABL, RET, TRK-A and FGFRs.1,2 PHA-739358 shows a dominant aurora kinase B inhibition-related cellular phenotype and induces a p53 status dependent endoreduplication. The compound has antitumor activity in spontaneous, transgenic and xenograft models of solid and hematologic tumors with occasional cures. It is active in a broad range of BCR-ABL positive and negative cell lines, including T315I BCR-ABL mutants. A decreased phosphorylation of histone H3 under PHA- 739358 treatment has been described as a pharmacodynamic biomarker of aurora kinase B inhibition in human skin at safe doses. Similarly the reduced CRKL phosphorylation documents the activity via BCR-ABL inhibition.1,3

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite

Paquette, R., Shah, N., Sawyers, C., Martinelli, G., Nicoll, J., & Chalukya, M. (2009). Pha-739358: a pan-aurora kinase inhibitor. Hematology Meeting Reports (formerly Haematologica Reports), 2(5). https://doi.org/10.4081/hmr.v2i5.743
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).